At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, David Carbone, MD, PhD, from The Ohio State University Wexner Medical Center, Columbus, OH, explains that there has been significant progress in the development of immunotherapy for lung cancer and clinical trial design in immunotherapy should be tailored to the patterns of response and outcomes observed for this approach.